Literature DB >> 12727799

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study.

Mirian Brink1, Anton F P M de Goeij, Matty P Weijenberg, Guido M J M Roemen, Marjolein H F M Lentjes, Marco M M Pachen, Kim M Smits, Adriaan P de Bruïne, R Alexandra Goldbohm, Piet A van den Brandt.   

Abstract

Activation of K-ras oncogene has been implicated in colorectal carcinogenesis, being mutated in 30-60% of the adenocarcinomas. In this study, 737 incident colorectal cancer (CRC) patients, originating from 120 852 men and women (55-69 years at baseline) participating in the Netherlands Cohort Study (NLCS), were studied in order to evaluate subgroups with respect to K-ras mutation status. Mutation analysis of the exon 1 fragment of the K-ras oncogene, spanning codons 8-29, was performed on archival colorectal adenocarcinoma samples of all patients using macrodissection, nested PCR and direct sequencing of purified fragments. The method of mutation detection was validated by the confirmation of reported K-ras status in CRC cell lines, a good correlation between fresh-frozen and routinely fixed, paraffin-embedded tissue, a detection limit of 5% mutated DNA and a good reproducibility. Various types of K-ras mutations were evaluated with respect to tumour sub-localization, Dukes' stage and tumour differentiation. In 37% (271/737) of the patients, the exon 1 fragment of K-ras gene was found to be mutated. The predominant mutations are G>A transitions and G>T transversions, and codons 12 and 13 are the most frequently affected codons. Patients with a rectal tumour were found to have the highest frequency of G>T transversions as compared with patients with a colon or rectosigmoid tumour. This difference appeared to be confined to women with a rectal tumour harbouring G>T transversions. No significant differences were observed for Dukes' stage with respect to types of K-ras mutation, which does not support direct involvement of the K-ras oncogene in adenocarcinoma progression. The equal distribution of K-ras mutations among cases with or without a family history of colorectal cancer argues against an important role for this mutation in familial colorectal cancer, and could imply that K-ras mutations are more probably involved in environmental mechanisms of colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727799     DOI: 10.1093/carcin/bgg009

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  101 in total

1.  No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections.

Authors:  Teppei Morikawa; Kaori Shima; Aya Kuchiba; Mai Yamauchi; Noriko Tanaka; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Mohan Brahmandam; Janina A Longtine; Neal I Lindeman; Charles S Fuchs; Shuji Ogino
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

2.  Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations.

Authors:  Enkh-Amar Yadamsuren; Szilvia Nagy; Laszlo Pajor; Agnes Lacza; Barna Bogner
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

3.  Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

4.  Expression of IARS2 gene in colon cancer and effect of its knockdown on biological behavior of RKO cells.

Authors:  Ling Zhong; Yi Zhang; Jing-Yu Yang; Liang-Fa Xiong; Tao Shen; Ya-Lian Sa; Yi-Ming O'Yang; Si-Hui Zhao; Jia-Yong Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.

Authors:  Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  Tumour Biol       Date:  2015-12-10

6.  Integrating anti-EGFR therapies in metastatic colorectal cancer.

Authors:  Sigurdis Haraldsdottir; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2013-09

7.  Duodenal carcinoma in MUTYH-associated polyposis.

Authors:  M Nielsen; J W Poley; S Verhoef; M van Puijenbroek; M M Weiss; G T Burger; C J Dommering; H F A Vasen; E J Kuipers; A Wagner; H Morreau; F J Hes
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

Review 8.  The role of targeted therapy in the treatment of advanced colorectal cancer.

Authors:  Marwan Fakih
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

9.  Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.

Authors:  Ran Tao; Qiang Li; Xiaofei Gao; Lilin Ma
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

10.  Oncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cells.

Authors:  Byong Hoon Yoo; Xue Wu; Yongling Li; Mehnaaz Haniff; Takehiko Sasazuki; Senji Shirasawa; Eeva-Liisa Eskelinen; Kirill V Rosen
Journal:  J Biol Chem       Date:  2009-09-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.